Meeting
2015 ASCO Annual Meeting
Effectiveness and tolerability of maintenance capecitabine administrated to patients with metastatic pancreatic cancer treated with first line FOLFIRINOX.
Authors
Juliette Reure
Centre Antoine Lacassagne, Nice, France
Juliette Reure , Philippe Follana , Jocelyn Gal , Ludovic Evesque , Gerard Cavaglione , Angelique Saint , Eric Francois
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 4120)
DOI
10.1200/jco.2015.33.15_suppl.4120
Abstract #
4120
Poster Bd #
232
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
The value of tissue protein expression as a predictor of efficacy for first or second-line therapy (tx) in metastatic ductal pancreas cancer (PDAC) in patients (pts) receiving either gemcitabine (G)-based tx or 5FU (F)-based tx.
First Author: Lauren Carcas
Poster
2023 ASCO Annual Meeting
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.
First Author: Vincent Chung
Poster
2020 ASCO Virtual Scientific Program
HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.
First Author: Shintaro Nakano
Poster
2018 Gastrointestinal Cancers Symposium
Activity and safety of Nab-FOLFIRI and Nab-FOLFOX as first-line treatment for metastatic pancreatic cancer (phase II NabucCO study).
First Author: Elisa Giommoni